{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:15:16Z","timestamp":1767845716048,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,11,13]],"date-time":"2014-11-13T00:00:00Z","timestamp":1415836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s10689-014-9771-y","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T17:26:09Z","timestamp":1415985969000},"page":"309-316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel\u2013Lindau (VHL) disease: clinical outcome and patterns of radiological response"],"prefix":"10.1007","volume":"14","author":[{"given":"Anna","family":"Roma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Brunello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Zamarchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Bezzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Pomerri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Zovato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Opocher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorina","family":"Zagonel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,13]]},"reference":[{"key":"9771_CR1","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","volume":"361","author":"RR Lonser","year":"2003","unstructured":"Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH (2003) von Hippel\u2013Lindau disease. Lancet 361:2059\u20132067","journal-title":"Lancet"},{"key":"9771_CR2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1399-0004.2007.00827.x","volume":"72","author":"FJ Hes","year":"2007","unstructured":"Hes FJ, van der Luijt RB, Janssen AL, Zewald RA, de Jong GJ, Lenders JW, Links TP, Luyten GP, Sijmons RH, Eussen HJ, Halley DJ, Lips CJ, Pearson PL, van den Ouweland AM, Majoor-Krakauer DF (2007) Frequency of von Hippel\u2013Lindau germline mutations in classic and non-classic von Hippel\u2013Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification. Clin Genet 72:122\u2013129","journal-title":"Clin Genet"},{"key":"9771_CR3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/humu.1380050109","volume":"5","author":"F Chen","year":"1995","unstructured":"Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G et al (1995) Germline mutations in the von Hippel\u2013Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5:66\u201375","journal-title":"Hum Mutat"},{"key":"9771_CR4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271\u2013275","journal-title":"Nature"},{"key":"9771_CR5","first-page":"3803","volume":"62","author":"M Zatyka","year":"2002","unstructured":"Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER (2002) Identification of cyclin D1 and other novel targets for the von Hippel\u2013Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel\u2013Lindau disease. Cancer Res 62:3803\u20133811","journal-title":"Cancer Res"},{"key":"9771_CR6","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/MCB.24.8.3251-3261.2004","volume":"24","author":"HN Stickle","year":"2004","unstructured":"Stickle HN, Chung J, Klco JM, Hill RP, Kaelin WG Jr, Ohh M (2004) pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol 24:3251\u20133261","journal-title":"Mol Cell Biol"},{"key":"9771_CR7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16\u201324","journal-title":"J Clin Oncol"},{"key":"9771_CR8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40265-013-0043-1","volume":"73","author":"B Escudier","year":"2013","unstructured":"Escudier B, Albiges L, Sonpavde G (2013) Optimal management of metastatic renal cell carcinoma: current status. Drugs 73:427\u2013438","journal-title":"Drugs"},{"key":"9771_CR9","doi-asserted-by":"crossref","first-page":"7582","DOI":"10.1158\/1078-0432.CCR-09-2131","volume":"15","author":"AC Young","year":"2009","unstructured":"Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ, Banks RE (2009) Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 15:7582\u20137592","journal-title":"Clin Cancer Res"},{"key":"9771_CR10","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/cncr.24232","volume":"115","author":"WG Kaelin","year":"2009","unstructured":"Kaelin WG (2009) Treatment of kidney\u00a0cancer: insights provided by the VHL tumor-suppressor protein. Cancer 115:2262\u20132272","journal-title":"Cancer"},{"key":"9771_CR11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"9771_CR12","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753\u20131759","journal-title":"J Clin Oncol"},{"key":"9771_CR13","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584\u20133590","journal-title":"J Clin Oncol"},{"key":"9771_CR14","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N, AVOREN Trial investigators (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103\u20132111","journal-title":"Lancet"},{"key":"9771_CR15","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","volume":"49","author":"CN Sternberg","year":"2013","unstructured":"Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID (2013) A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 49:1287\u20131296","journal-title":"Eur J Cancer"},{"key":"9771_CR16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1464-410X.2006.06376.x","volume":"98","author":"BI Rini","year":"2006","unstructured":"Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM (2006) Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and von Hippel\u2013Lindau gene status. BJU Int 98:756\u2013762","journal-title":"BJU Int"},{"key":"9771_CR17","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.juro.2008.05.015","volume":"180","author":"TK Choueiri","year":"2008","unstructured":"Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R (2008) von Hippel\u2013Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 180:860\u2013865","journal-title":"J Urol"},{"key":"9771_CR18","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/annonc\/mdr011","volume":"22","author":"E Jonasch","year":"2011","unstructured":"Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, Tannir NM, Gombos DS, Fuller GN, Matin SF (2011) Pilot trial of sunitinib therapy in patients with von Hippel\u2013Lindau disease. Ann Oncol 22:2661\u20132666","journal-title":"Ann Oncol"},{"key":"9771_CR19","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","volume":"10","author":"ME Gore","year":"2009","unstructured":"Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Sch\u00f6ffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10:757\u2013763","journal-title":"Lancet Oncol"},{"key":"9771_CR20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/MPA.0b013e31822a645e","volume":"41","author":"T Ali","year":"2012","unstructured":"Ali T, Kandil D, Piperdi B (2012) Long-term disease control with sunitinib in a patient with metastatic pancreatic neuroendocrine tumour (NET) associated with von Hipple\u2013Lindau syndrome (VHL). Pancreas 41:492\u2013493","journal-title":"Pancreas"},{"key":"9771_CR21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, H\u00f6rsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501\u2013513","journal-title":"N Engl J Med"},{"key":"9771_CR22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/CAD.0b013e3283442039","volume":"22","author":"A Ravaud","year":"2011","unstructured":"Ravaud A, Bello CL (2011) Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice. Anticancer Drugs 22:377\u2013383","journal-title":"Anticancer Drugs"},{"key":"9771_CR23","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/annonc\/mds431","volume":"24","author":"A Brunello","year":"2013","unstructured":"Brunello A, Basso U, Sacco C, Sava T, De Vivo R, Camerini A, Barile C, Roma A, Maruzzo M, Falci C, Zagonel V (2013) Safety and activity of sunitinib in elderly patients (\u226570\u00a0years) with metastatic renal cell carcinoma: a multicenter study. Ann Oncol 24:336\u2013342","journal-title":"Ann Oncol"},{"key":"9771_CR24","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/sj.bjc.6605567","volume":"102","author":"AA Veldt van der","year":"2010","unstructured":"van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E (2010) Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 102:803\u2013809","journal-title":"Br J Cancer"},{"key":"9771_CR25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/ki.2009.552","volume":"77","author":"C Porta","year":"2010","unstructured":"Porta C, Paglino C, De Amici M, Quaglini S, Sacchi L, Imarisio I, Canipari C (2010) Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 77:809\u2013815","journal-title":"Kidney Int"},{"key":"9771_CR26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/annonc\/mdq323","volume":"22","author":"A Gradilone","year":"2011","unstructured":"Gradilone A, Naso G, Raimondi C, Cortesi E, Gandini O, Vincenzi B, Saltarelli R, Chiapparino E, Spremberg F, Cristofanilli M, Frati L, Aglian\u00f2 AM, Gazzaniga P (2011) Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann Oncol 22:86\u201392","journal-title":"Ann Oncol"},{"key":"9771_CR27","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/bjc.2012.388","volume":"107","author":"E Rossi","year":"2012","unstructured":"Rossi E, Fassan M, Aieta M, Zilio F, Celadin R, Borin M, Grassi A, Troiani L, Basso U, Barile C, Sava T, Lanza C, Miatello L, Jirillo A, Rugge M, Indraccolo S, Cristofanilli M, Amadori A, Zamarchi R (2012) Dynamic changes of live\/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. Br J Cancer 107:1286\u20131294","journal-title":"Br J Cancer"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-014-9771-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10689-014-9771-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-014-9771-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T17:46:14Z","timestamp":1559238374000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10689-014-9771-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,13]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["9771"],"URL":"https:\/\/doi.org\/10.1007\/s10689-014-9771-y","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,13]]}}}